Bristol Myers Squibb (BMY) announces Phase 3 ALOFT-IPF trial evaluating admilparant in adults with idiopathic pulmonary fibrosis met primary endpoint

Positive Phase 3 readouts in idiopathic pulmonary fibrosis sit in a category with a thin precedent set: only two antifibrotics have historically secured approval in this indication, and both decelerate decline rather than reverse it, so any agent hitting its primary endpoint on lung function or progression immediately enters a small competitive field. The pattern in comparable late-stage respiratory and fibrosis wins has been a sharp single-name move on the day, with the durability of the re-rating hinging on the secondary endpoints, the safety discontinuation rate, and whether the magnitude of effect clears the bar set by the standard of care rather than merely reaching statistical significance. The distinction that matters here is between a trial designed to support filing on its own and one positioned as confirmatory; press-release language around whether the programme proceeds to regulatory submission is the tell. Watch next for full data at a medical congress, since topline press releases in past episodes of this kind have occasionally been revised in interpretation once complete datasets, subgroup performance, and adverse event detail are visible. For Bristol Myers specifically, pipeline successes have historically been weighed against its looming patent-exposure narrative, so the follow-on question is whether this asset is sized to offset that gap. Peer read-across to other IPF and fibrosis developers is the standard second-order trade in such episodes.